Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
29611083
DOI
10.1007/s10067-018-4074-6
PII: 10.1007/s10067-018-4074-6
Knihovny.cz E-zdroje
- Klíčová slova
- Antirheumatic agents, Clinical trial, Geographic locations, Golimumab, Rheumatoid arthritis,
- MeSH
- antirevmatika terapeutické užití MeSH
- dospělí MeSH
- indukce remise MeSH
- kombinovaná farmakoterapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- methotrexát terapeutické užití MeSH
- mladiství MeSH
- mladý dospělý MeSH
- monoklonální protilátky terapeutické užití MeSH
- prospektivní studie MeSH
- revmatoidní artritida farmakoterapie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stupeň závažnosti nemoci MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
- Názvy látek
- antirevmatika MeSH
- golimumab MeSH Prohlížeč
- methotrexát MeSH
- monoklonální protilátky MeSH
GO-MORE (NCT00975130) was a large open-label, multinational, multicenter, prospective phase 3 trial evaluating add-on therapy with golimumab in biologic-naïve patients with active rheumatoid arthritis (RA). The objective of this post hoc analysis was to examine regional differences in baseline disease activity and remission rates following golimumab treatment for RA. This was a planned, descriptive post hoc analysis of data from the GO-MORE trial. Baseline disease activity and remission were defined as moderate or severe based on EULAR criteria. This analysis included 3280 participants from the GO-MORE trial. All participants included in this analysis had high or moderate disease activity at baseline. At baseline, high disease activity was least common in Europe (71.0%), Canada (77.0%), and the Middle East (78.2%) and most common in Latin America (90.7%), South Africa (91.5%), and Asia (92.5%). Month 6 remission rates were highest in South Africa (29.1%), Europe (27.9%), and the Middle East (27.3%) and lowest in Canada (19.7%), Latin America (17.2%), and Asia (15.0%). Higher rates of remission in each geographical region generally corresponded with lower baseline disease activity. We suspect that access to care and implementation of the treat-to-target strategy were the most important determinants, but this apparent relationship needs to be confirmed in further studies that include a statistical analysis of prognostic indicators.
AGAR UFM 6 Avenida 7 55 zona 10 01010 Guatemala City Guatemala
Institute of Rheumatology Na Slupi 4 128 50 Praha 2 Czech Republic
MSD Clos du Lynx 5 1200 Woluwe Saint Lambert Belgium
MSD Via Vitorchiano 151 00189 Rome RM Italy
Sheba Medical Center Tel Hashomer Emek HaEla St 1 Ramat Gan Israel
Zobrazit více v PubMed
Ann Rheum Dis. 2014 Aug;73(8):1477-86 PubMed
Rheumatology (Oxford). 2016 Aug;55(8):1466-76 PubMed
Reumatol Clin. 2015 May-Jun;11(3):144-50 PubMed
Rheum Dis Clin North Am. 2009 Nov;35(4):745-57, vii-viii PubMed
Arthritis Care Res (Hoboken). 2012 Aug;64(8):1135-43 PubMed
Ann Rheum Dis. 2014 Mar;73(3):492-509 PubMed
Ann Rheum Dis. 2016 Jan;75(1):3-15 PubMed
Ann Rheum Dis. 2010 Apr;69(4):631-7 PubMed
Ann Rheum Dis. 2016 Mar;75(3):540-6 PubMed
Lancet. 2009 Jul 18;374(9685):210-21 PubMed
Ann Rheum Dis. 2009 Nov;68(11):1666-72 PubMed
Ann Rheum Dis. 2013 Mar;72 (3):381-9 PubMed
Arthritis Rheum. 2011 May;63(5):1200-10 PubMed
